Challenges and future of HER2-positive gastric cancer therapy

Frontiers in Oncology

Oncology

Jiwu Guo¹  Xiao Wang¹  Chenzhe Ma¹  Bo Yang¹  Yumin Li¹ 

[1] The Second Clinical Medical College, Lanzhou University, Lanzhou, China;Key Laboratory of the Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou, China;

关键词: gastric cancer;    receptor ErbB-2;    HER2;    Her2 resistance;    trastuzumab;   

DOI  :  10.3389/fonc.2023.1080990

 received in 2022-10-26, accepted in 2023-01-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

Gastric cancer is the fifth most common cancer worldwide, and the treatment of advanced gastric cancer has relatively little progress. With the continuous development of molecularly targeted therapy for tumors, it has been discovered that human epidermal growth factor receptor 2 (HER2) contributes to the poor prognosis and pathogenesis of various cancers. In order to treat HER2-positive advanced gastric cancer, Trastuzumab has emerged as the first first-line targeted medication used in conjunction with chemotherapy. The consequent trastuzumab resistance has become an important issue, and various new HER2-targeted gastric cancer drugs are emerging to address this challenge. This review’s primary concern is the drug mechanism of various HER2-positive gastric cancer targeted therapy and fresh techniques of detection.

【 授权许可】

Unknown   
Copyright © 2023 Ma, Wang, Guo, Yang and Li